Journal
JOURNAL OF VIROLOGY
Volume 82, Issue 18, Pages 9283-9287Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01047-08
Keywords
-
Categories
Funding
- National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19 AI-057319]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057319] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Among 17 HLA-A2-positive healthy adults, CD8(+) T-cell responses against an HLA-A2-restricted matrix protein 1 (M1) epitope increased after immunization with trivalent inactivated influenza vaccine (TIV) in two individuals. The presence of M1 in TIV was confirmed by Western blotting. T-cell cytotoxicity assays showed that TIV is processed and the epitope is presented by antigen-presenting cells to an M1 epitope-specific CD8(+) T-cell line for specific lysis. These data show that TIV, which is formulated to contain surface glycoproteins to induce serotype-specific antibody responses, also contains M1, capable of inducing subtype cross-reactive CD8(+) T-cell responses in some vaccinees.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available